A Phase 3 interventional study of Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution and Ketotifen fumarate ophthalmic solution 0.035% in Seasonal Allergic Conjunctivitis, sponsored by Bausch & Lomb Incorporated. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. — none open to participants now, none under way, none of them phase 3. Conjunctivitis, Allergic · Bausch Health Companies Inc..
Among the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc., this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 11 in phase 3, and was the 15th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →None of the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. is open now. The open studies under Conjunctivitis, Allergic, anywhere →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 229 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 144 across the 17 interventional studies. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must:
Exclusion Criteria:
Subjects may not:
have a history of mild persistent, moderate or severe asthma within the preceding 5 years according to the National Heart, Blood, and Lung Institute classification (with the exception of exercise induced asthma).
Note: Subjects with fall induced asthma that is either mild persistent (defined as >1 per week, but \<1 per day), moderate persistent, or severe persistent will be excluded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%
Drug: Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%
Drug: Brimonidine tartrate ophthalmic solution 0.025%
Vehicle ophthalmic solution
Drug: Experimental: Vehicle ophthalmic solution
Drug page: Brimonidine
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Ketotifen fumarate ophthalmic solution 0.035%
Brimonidine tartrate ophthalmic solution 0.025%
Experimental: Vehicle ophthalmic solution
Ocular Itching Symptom Score
Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.
Time frame: Assessed up to 480 minutes post-instillation of assigned IP
Ocular Redness Measured by Ocular Itching Scale
Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
Time frame: Assessed up to 480 minutes post-instillation of assigned IP
Tearing Measured by Watery Eyes Scale
Tearing evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, NOT allowing half unit increments), with 4 being the worse outcome.
Time frame: up to 480 minutes post-instillation of assigned IP
Lid Swelling Measured by Eyelid Swelling Scale
Lid swelling evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-3 scale, NOT allowing half unit increments), with 3 being the worst outcome
Time frame: up to 480 minutes post-instillation of assigned IP
Chemosis Evaluated
Chemosis evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
Time frame: up to 480 minutes post-instillation of assigned IP
| Milestone | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Started | 58 | 57 | 58 | 56 |
| Completed | 57 | 56 | 56 | 56 |
| Not completed | 1 | 1 | 2 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.
| score on a scale | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visit 2, Before Qualification ABC | 0.175 ± 0.6031 | 0.085 ± 0.3136 | 0.267 ± 0.7549 | 0.098 ± 0.3493 |
| Visit 2, 90 Minutes during Qualification ABC (Baseline) | 2.728 ± 0.5830 | 2.719 ± 0.5310 | 2.659 ± 0.4581 | 2.647 ± 0.5174 |
| Visit 2, 10 min Post-Instillation | 1.807 ± 1.0501 | 1.808 ± 0.8712 | 1.991 ± 1.0163 | 2.022 ± 0.8302 |
| Visit 2, 30 min Post-Instillation | 1.443 ± 0.8914 | 1.335 ± 0.8275 | 1.513 ± 1.0621 | 1.790 ± 0.8979 |
| Visit 2, 60 min Post-Instillation | 1.110 ± 0.8737 | 1.205 ± 0.9171 | 1.220 ± 0.9425 | 1.438 ± 0.7720 |
| Visit 2, 360 min Post-Instillation | 0.811 ± 0.8599 | 0.723 ± 0.7365 | 1.125 ± 0.9485 | 1.089 ± 1.0252 |
| Visit 2, 420 min Post-Instillation | 0.851 ± 0.8568 | 0.656 ± 0.7348 | 1.078 ± 0.9461 | 0.978 ± 0.8624 |
| Visit 2, 480 min Post-Instillation | 0.961 ± 1.0020 | 0.777 ± 0.8786 | 1.009 ± 0.9188 | 1.063 ± 0.9011 |
Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
| score on a scale | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visit 2, Before Qualification ABC | 1.218 ± 0.5815 | 1.327 ± 0.5771 | 1.384 ± 0.5815 | 1.268 ± 0.6464 |
| Visit 2, 90 Minutes during Qualification ABC (Baseline) | 2.469 ± 0.5430 | 2.500 ± 0.5045 | 2.642 ± 0.5832 | 2.478 ± 0.4984 |
| Visit 2, 10 min Post-Instillation | 1.127 ± 0.8253 | 2.116 ± 0.6178 | 1.293 ± 0.8194 | 2.268 ± 0.6195 |
| Visit 2, 30 min Post-Instillation | 0.934 ± 0.7388 | 1.911 ± 0.6421 | 1.103 ± 0.7609 | 2.165 ± 0.7011 |
| Visit 2, 60 min Post-Instillation | 0.904 ± 0.6924 | 1.795 ± 0.7184 | 1.026 ± 0.7517 | 2.098 ± 0.6787 |
| Visit 2, 360 min Post-Instillation | 1.316 ± 0.8245 | 1.723 ± 0.7608 | 1.405 ± 0.6896 | 1.955 ± 0.6416 |
| Visit 2, 420 min Post-Instillation | 1.456 ± 0.7936 | 1.759 ± 0.7847 | 1.582 ± 0.6873 | 1.933 ± 0.6440 |
| Visit 2, 480 min Post-Instillation | 1.553 ± 0.8125 | 1.929 ± 0.8471 | 1.832 ± 0.7757 | 2.063 ± 0.7043 |
Tearing evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, NOT allowing half unit increments), with 4 being the worse outcome.
| score on a scale | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visit 2, Before Qualification ABC | 0.12 ± 0.503 | 0.04 ± 0.197 | 0.22 ± 0.773 | 0.13 ± 0.429 |
| Visit 2, 90 Minutes during Qualification ABC (Baseline) | 1.34 ± 1.192 | 1.23 ± 0.977 | 1.41 ± 1.219 | 1.10 ± 0.997 |
| Visit 2, 10 min Post-Instillation | 1.21 ± 1.056 | 1.10 ± 0.988 | 1.16 ± 1.056 | 1.14 ± 0.971 |
| Visit 2, 10 min Post-Instillation change from baseline | -0.13 ± 0.961 | -0.13 ± 0.839 | -0.25 ± 0.768 | 0.04 ± 0.945 |
| Visit 2, 30 min Post-Instillation | 0.77 ± 0.835 | 0.79 ± 0.883 | 0.94 ± 0.937 | 0.98 ± 0.958 |
| Visit 2, 30 min Post-Instillation change from baseline | -0.57 ± 1.006 | -0.44 ± 0.826 | -0.47 ± 0.991 | -0.12 ± 0.853 |
| Visit 2, 60 min Post-Instillation | 0.66 ± 0.757 | 0.65 ± 0.909 | 0.73 ± 0.865 | 0.76 ± 0.879 |
| Visit 2, 60 min Post-Instillation change from baseline | -0.68 ± 0.989 | -0.58 ± 1.048 | -0.67 ± 1.024 | -0.34 ± 0.944 |
| Visit 2, 360 min Post-Instillation | 0.42 ± 0.667 | 0.41 ± 0.668 | 0.64 ± 0.883 | 0.65 ± 0.744 |
| Visit 2, 360 min Post-Instillation change from baseline | -0.92 ± 1.113 | -0.82 ± 0.811 | -0.77 ± 1.035 | -0.45 ± 1.030 |
| Visit 2, 420 min Post-Instillation | 0.50 ± 0.726 | 0.34 ± 0.581 | 0.68 ± 0.945 | 0.46 ± 0.582 |
| Visit 2, 420 min Post-Instillation change from baseline | -0.84 ± 1.123 | -0.89 ± 0.857 | -0.72 ± 1.085 | -0.64 ± 1.065 |
| Visit 2, 480 min Post-Instillation | 0.54 ± 0.761 | 0.27 ± 0.539 | 0.56 ± 0.720 | 0.46 ± 0.785 |
| Visit 2, 480 min Post-Instillation change from baseline | -0.81 ± 1.097 | -0.96 ± 0.830 | -0.84 ± 1.056 | -0.63 ± 1.102 |
Lid swelling evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-3 scale, NOT allowing half unit increments), with 3 being the worst outcome
| score on a scale | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visit 2, Before Qualification ABC | 0.09 ± 0.434 | 0.00 ± 0.000 | 0.11 ± 0.409 | 0.04 ± 0.187 |
| Visit 2, 90 Minutes during Qualification ABC (Baseline) | 1.04 ± 0.972 | 0.70 ± 0.883 | 1.05 ± 0.921 | 0.92 ± 0.873 |
| Visit 2, 10 min Post-Instillation | 0.85 ± 0.973 | 0.77 ± 0.874 | 1.03 ± 0.957 | 0.98 ± 0.904 |
| Visit 2, 10 min Post-Instillation change from baseline | -0.18 ± 0.748 | 0.07 ± 0.606 | -0.03 ± 0.652 | 0.06 ± 0.714 |
| Visit 2, 30 min Post-Instillation | 0.75 ± 0.851 | 0.75 ± 0.905 | 0.72 ± 0.750 | 0.90 ± 0.881 |
| Visit 2, 30 min Post-Instillation change from baseline | -0.28 ± 0.851 | 0.05 ± 0.644 | -0.34 ± 0.740 | -0.02 ± 0.798 |
| Visit 2, 60 min Post-Instillation | 0.65 ± 0.802 | 0.64 ± 0.841 | 0.59 ± 0.744 | 0.81 ± 0.902 |
| Visit 2, 60 min Post-Instillation change from baseline | -0.39 ± 0.835 | -0.05 ± 0.644 | -0.47 ± 0.805 | -0.11 ± 0.785 |
| Visit 2, 360 min Post-Instillation | 0.48 ± 0.762 | 0.43 ± 0.817 | 0.61 ± 0.864 | 0.67 ± 0.886 |
| Visit 2, 360 min Post-Instillation change from baseline | -0.55 ± 0.817 | -0.27 ± 0.707 | -0.44 ± 0.869 | -0.25 ± 0.929 |
| Visit 2, 420 min Post-Instillation | 0.60 ± 0.832 | 0.44 ± 0.695 | 0.61 ± 0.838 | 0.61 ± 0.824 |
| Visit 2, 420 min Post-Instillation change from baseline | -0.44 ± 0.921 | -0.26 ± 0.681 | -0.44 ± 0.822 | -0.31 ± 0.877 |
| Visit 2, 480 min Post-Instillation | 0.55 ± 0.777 | 0.42 ± 0.731 | 0.55 ± 0.826 | 0.58 ± 0.857 |
| Visit 2, 480 min Post-Instillation change from baseline | -0.48 ± 0.802 | -0.28 ± 0.750 | -0.50 ± 0.827 | -0.34 ± 0.895 |
Chemosis evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.
| score on a scale | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visit 2, Before Qualification ABC | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.004 ± 0.0328 | 0.022 ± 0.1372 |
| Visit 2, 90 Minutes during Qualification ABC (Baseline) | 0.298 ± 0.7249 | 0.143 ± 0.3626 | 0.134 ± 0.3811 | 0.129 ± 0.3843 |
| Visit 2, 10 min Post-Instillation | 0.228 ± 0.5830 | 0.121 ± 0.3371 | 0.086 ± 0.2502 | 0.156 ± 0.4537 |
| Visit 2, 10 min Post-Instillation change from baseline | -0.070 ± 0.3196 | -0.022 ± 0.2490 | -0.047 ± 0.1957 | 0.027 ± 0.3804 |
| Visit 2, 30 min Post-Instillation | 0.158 ± 0.5274 | 0.094 ± 0.3110 | 0.039 ± 0.1609 | 0.134 ± 0.4290 |
| Visit 2, 30 min Post-Instillation change from baseline | -0.140 ± 0.4092 | -0.049 ± 0.2877 | -0.095 ± 0.2683 | 0.004 ± 0.5319 |
| Visit 2, 60 min Post-Instillation | 0.154 ± 0.5298 | 0.094 ± 0.2883 | 0.052 ± 0.1973 | 0.112 ± 0.3597 |
| Visit 2, 60 min Post-Instillation change from baseline | -0.145 ± 0.4405 | -0.049 ± 0.2450 | -0.082 ± 0.2406 | -0.018 ± 0.4764 |
| Visit 2, 360 min Post-Instillation | 0.114 ± 0.3662 | 0.094 ± 0.2960 | 0.069 ± 0.2556 | 0.089 ± 0.2756 |
| Visit 2, 360 min Post-Instillation change from baseline | -0.184 ± 0.5561 | -0.049 ± 0.3706 | -0.065 ± 0.2321 | -0.040 ± 0.4258 |
| Visit 2, 420 min Post-Instillation | 0.105 ± 0.3502 | 0.067 ± 0.2050 | 0.082 ± 0.2624 | 0.076 ± 0.2608 |
| Visit 2, 420 min Post-Instillation change from baseline | -0.193 ± 0.5408 | -0.076 ± 0.2564 | -0.052 ± 0.2555 | -0.054 ± 0.4439 |
| Visit 2, 480 min Post-Instillation | 0.088 ± 0.3006 | 0.076 ± 0.2232 | 0.091 ± 0.2678 | 0.058 ± 0.2184 |
| Visit 2, 480 min Post-Instillation change from baseline | -0.211 ± 0.5505 | -0.067 ± 0.2919 | -0.043 ± 0.2815 | -0.071 ± 0.4490 |
Collected over Assessed for approximately 8 hours after treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | 0/57 (0%) | 0/57 (0%) | 1/57 (1.8%) |
| Ketotifen Fumarate Ophthalmic Solution 0.035% | 0/56 (0%) | 0/56 (0%) | 6/56 (10.7%) |
| Brimonidine Tartrate Ophthalmic Solution 0.025% | 0/58 (0%) | 0/58 (0%) | 2/58 (3.4%) |
| Vehicle Ophthalmic Solution | 0/56 (0%) | 0/56 (0%) | 5/56 (8.9%) |
| Event | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Ketotifen Fumarate Ophthalmic Solution 0.035% | Brimonidine Tartrate Ophthalmic Solution 0.025% | Vehicle Ophthalmic Solution |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 1/57 | 2/56 | 2/58 | 2/56 |
| Ocular hyperaemiaEye disorders | 0/57 | 2/56 | 0/58 | 1/56 |
| Conjunctival oedemaEye disorders | 0/57 | 2/56 | 0/58 | 0/56 |
| Eyelid exfoliationEye disorders | 0/57 | 0/56 | 0/58 | 1/56 |
| Erythema of eyelidEye disorders | 0/57 | 0/56 | 0/58 | 1/56 |
| Age, Continuous(years) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| Mean | 35.5 ± 15.06 | 35.0 ± 12.28 | 37.1 ± 16.05 | 37.1 ± 16.61 | 36.2 ± 15.03 |
| Age, Customized(Participants) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| Less than 65 years | 52 | 55 | 55 | 50 | 212 |
| Greater or equal to 65 years | 5 | 1 | 3 | 6 | 15 |
| Sex: Female, Male(Participants) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| Female | 34 | 38 | 39 | 39 | 150 |
| Male | 23 | 18 | 19 | 17 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 14 | 14 | 15 | 55 |
| Not Hispanic or Latino | 45 | 42 | 44 | 41 | 172 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 12 | 10 | 12 | 10 | 44 |
| Asian | 1 | 3 | 1 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 7 | 9 | 12 | 35 |
| White | 36 | 36 | 34 | 31 | 137 |
| More than one race | 1 | 0 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56) | Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56) | Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56) | Vehicle Ophthalmic Solution (n = 56) | Total |
|---|---|---|---|---|---|
| United States | 57 | 56 | 58 | 56 | 227 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Aug 2023, 8 months.
Results were first posted in Jul 2025, 1 year 10 months after primary completion.
Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 8 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine